Filing Details
- Accession Number:
- 0001847903-25-000113
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-06-25 19:42:51
- Reporting Period:
- 2025-06-24
- Filing Date:
- 2025-06-25
- Accepted Time:
- 2025-06-25 19:42:51
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1847903 | Centessa Pharmaceuticals Plc | CNTA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 2074392 | Alberto Mario Accardi | C/O Centessa Pharmaceuticals Plc 3Rd Fl., 1 Ashley Rd, Altrincham Cheshire X0 WA14 2DT | President, Orexin Program | No | Yes | No | No |
Transaction Summary
| Sold: | 15,000 shares | Avg. Price: $14.00 | Total Value: $210,000.00 |
| Number of Shares After Transactions: | 216,485 shares | ||
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Acquisiton | 2025-06-24 | 15,000 | $3.85 | 231,485 | No | 4 | M | Direct | |
| Ordinary Shares | Disposition | 2025-06-24 | 15,000 | $14.00 | 216,485 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Share Option (right to buy) | Disposition | 2025-06-24 | 15,000 | $0.00 | 15,000 | $3.85 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 15,300 | 2033-02-01 | No | 4 | M | Direct |
Footnotes
- The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2025.
- 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2023.
Billionaire Hedge Funds
